AIDS
MCID: HMN044
MIFTS: 73

Human Immunodeficiency Virus Type 1 (AIDS)

Categories: Cancer diseases, Genetic diseases, Immune diseases

Aliases & Classifications for Human Immunodeficiency Virus Type 1

MalaCards integrated aliases for Human Immunodeficiency Virus Type 1:

Name: Human Immunodeficiency Virus Type 1 57
Aids 57 75 55 3 17
Human Immunodeficiency Virus Type 1, Susceptibility to 57 29 6
Hiv/aids 57 43 3
Aids, Delayed/rapid Progression to 57 13
Hiv-1 Viremia, Susceptibility to 57 6
Rapid Progression to Aids from Hiv1 Infection 57
Human Immunodeficiency Virus I Infection 72
Acquired Immunodeficiency Syndrome 72
Hiv1 Infection, Resistance to 57
Hiv Type 1, Susceptibility to 57
Hiv Infection, Resistance to 57
Hiv/aids, Susceptibility to 57
Aids, Rapid Progression to 57
Aids, Slow Progression to 57
Hiv-1, Susceptibility to 57
Hiv-1, Resistance to 57
Aids, Resistance to 57
Hiv1, Resistance to 57
Hiv-Infection/aids 72
Hiv-1 Infection 17
Hiv1 Infection 57
Hiv-1 Viremia 57
Hiv Type 1 57
Hiv-1 57
Hiv1 57

Classifications:



External Ids:

OMIM 57 609423
UMLS 72 C0001175 C0276500 C0497169

Summaries for Human Immunodeficiency Virus Type 1

MedlinePlus : 43 HIV stands for human immunodeficiency virus. It harms your immune system by destroying the white blood cells that fight infection. This puts you at risk for serious infections and certain cancers. AIDS stands for acquired immunodeficiency syndrome. It is the final stage of infection with HIV. Not everyone with HIV develops AIDS. HIV most often spreads through unprotected sex with a person who has HIV. It may also spread by sharing drug needles or through contact with the blood of a person who has HIV. Women can give it to their babies during pregnancy or childbirth. The first signs of HIV infection may be swollen glands and flu-like symptoms. These may come and go within two to four weeks. Severe symptoms may not appear until months or years later. A blood test can tell if you have HIV infection. Your health care provider can do the test, or you can use a home testing kit. Or to find free testing sites, call the national referral hotline at 1-800-CDC-INFO (1-800-232-4636 in English and en español; 1-888-232-6348 - TTY). There is no cure, but there are many medicines that fight HIV infection and lower the risk of infecting others. People who get early treatment can live with the disease for a long time. Strategies to reduce the risk of HIV infection include not having sex, limiting your number of sexual partners, never sharing needles, and using condoms the right way every time you have sex. People who are at high risk may take HIV prevention medicines.

MalaCards based summary : Human Immunodeficiency Virus Type 1, also known as aids, is related to aspergillosis and acquired immunodeficiency syndrome, and has symptoms including fever and pruritus. An important gene associated with Human Immunodeficiency Virus Type 1 is CXCL12 (C-X-C Motif Chemokine Ligand 12), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pentoxifylline and Bleomycin have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and bone, and related phenotypes are hematopoietic system and immune system

OMIM : 57 The pathogenesis of HIV infection and the progression from infection to AIDS vary significantly between exposed individuals. Infection occurs after the virus, which has macrophage (M)- and T lymphocyte (T)-tropic strains and more than 12 subtypes, survives an array of nonspecific, nongenetic environmental and host factors. (609423)

CDC : 3 HIV is a virus spread through certain body fluids that attacks the body's immune system, specifically the CD4 cells, often called T cells. Over time, HIV can destroy so many of these cells that the body can't fight off infections and disease. These special cells help the immune system fight off infections. Untreated, HIV reduces the number of CD4 cells (T cells) in the body. This damage to the immune system makes it harder and harder for the body to fight off infections and some other diseases. Opportunistic infections or cancers take advantage of a very weak immune system and signal that the person has AIDS. Learn more about the stages of HIV and how to know whether you have HIV.

Wikipedia : 75 Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) is a spectrum... more...

Related Diseases for Human Immunodeficiency Virus Type 1

Diseases related to Human Immunodeficiency Virus Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2936)
# Related Disease Score Top Affiliating Genes
1 aspergillosis 33.6 IL10 IFNG CD209
2 acquired immunodeficiency syndrome 33.5 ITIH4 IL10 IFNG CCR5 CCR2 CCL3
3 human immunodeficiency virus infectious disease 33.2 ITIH4 IL10 IFNG CXCL12 CCR5 CCR2
4 viral infectious disease 32.9 TLR3 ITIH4 IL10 IFNG CD209 CCR5
5 encephalitis 32.5 TLR3 ITIH4 CD209 CCR5 CCL2
6 pulmonary tuberculosis 32.4 IL10 IFNG CCL3
7 bacterial infectious disease 32.3 TLR3 IL10 IFNG CCL2
8 meningitis 32.1 IL10 IFNG CCL3 CCL2
9 cytomegalovirus retinitis 32.1 IFNG CD9 CCR5 CCR2
10 allergic hypersensitivity disease 32.0 IL4R IL10 IFNG CCL11
11 demyelinating disease 32.0 IL10 IFNG CCL3 CCL2
12 toxoplasmosis 32.0 IL10 IFNG CCR5
13 schistosomiasis 32.0 IL10 IFNG CCL3
14 measles 32.0 TLR3 IFNG CD209
15 multiple sclerosis 31.9 IL10 IFNG CCR5 CCL3 CCL2
16 graft-versus-host disease 31.8 IL10 IFNG HLA-C
17 leptospirosis 31.7 IL10 IFNG CCL2
18 rheumatoid arthritis 31.7 IL10 IFNG CXCL12 CCR2 CCL3 CCL2
19 lymphadenitis 31.7 IL10 IFNG CD209
20 proteasome-associated autoinflammatory syndrome 1 31.7 IL10 IFNG CCL3 CCL2 CCL11
21 severe acute respiratory syndrome 31.7 IFNG CD209 CCL2
22 variola major 31.6 TLR3 IFNG CCL3
23 polyradiculoneuropathy 31.6 IL10 IFNG CXCL12
24 asthma 31.6 IL4R IL10 IFNG CXCL12 CCL3 CCL2
25 periodontitis 31.6 IL10 IFNG CCL2
26 hematopoietic stem cell transplantation 31.6 KIR3DL1 IL10 IFNG HLA-C
27 mouth disease 31.6 TLR3 IL10 IFNG
28 pneumonia 31.5 IL10 CCL3 CCL2 CCL11
29 chagas disease 31.5 IL10 IFNG CCR5 CCL3 CCL2
30 extrapulmonary tuberculosis 31.5 IL10 IFNG CCL2
31 uveitis 31.5 IL10 IFNG CCL2
32 west nile virus 31.5 TLR3 CD209 CCR5
33 sporotrichosis 31.4 IL10 IFNG
34 dermatitis, atopic 31.4 IL4R IL10 IFNG CCL11
35 allergic rhinitis 31.4 IL4R IL10 IFNG CCL11
36 bronchiolitis 31.4 IL4R IL10 IFNG CCL3 CCL11
37 trypanosomiasis 31.4 IL10 IFNG CCL3 CCL2
38 mucocutaneous leishmaniasis 31.4 TLR3 IL10 CCR5
39 skin disease 31.4 IL10 IFNG HLA-C CCL11
40 fungal meningitis 31.4 IL10 IFNG CCL2
41 ige responsiveness, atopic 31.3 IL4R IL10 IFNG
42 malaria 31.3 IL10 IFNG CCL3 CCL2 CCL11
43 pulmonary fibrosis, idiopathic 31.3 IFNG CXCR1 CXCL12 CCL3 CCL2
44 immune system disease 31.3 TLR3 IL10 IFNG
45 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 31.2 ITIH4 IL10 IFNG CXCL12 CD9 CD209
46 mycobacterium tuberculosis 1 31.2 IL10 IFNG CD209
47 tick-borne encephalitis 31.1 TLR3 IL10 CD209 CCR5
48 vulvovaginitis 31.1 IL10 CCL11
49 hand, foot and mouth disease 31.0 TLR3 IL10 IFNG
50 spondyloarthropathy 31.0 IL10 IFNG HLA-C

Graphical network of the top 20 diseases related to Human Immunodeficiency Virus Type 1:



Diseases related to Human Immunodeficiency Virus Type 1

Symptoms & Phenotypes for Human Immunodeficiency Virus Type 1

Clinical features from OMIM:

609423

UMLS symptoms related to Human Immunodeficiency Virus Type 1:


fever, pruritus

MGI Mouse Phenotypes related to Human Immunodeficiency Virus Type 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.06 CCL11 CCR2 CCR5 CD9 CX3CR1 CXCL12
2 immune system MP:0005387 10.03 CCL11 CCL2 CCR2 CCR5 CD9 CX3CR1
3 liver/biliary system MP:0005370 9.7 CCR2 CCR5 CXCL12 IFNG IL10 IL4R
4 neoplasm MP:0002006 9.43 CCR2 CCR5 IFNG IL10 ITIH4 TLR3
5 respiratory system MP:0005388 9.17 CCL11 CCR2 CD9 IFNG IL10 IL4R

Drugs & Therapeutics for Human Immunodeficiency Virus Type 1

DrugBank drugs 16 :

(show all 22)
# Drug Name Indication DrugBank ID
1 Abacavir For the treatment of HIV-1 infection, in combination with other antiretroviral agents. DB01048
2 Atazanavir Used in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. DB01072
3 Cobicistat Cobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of cobicistat is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir or tipranavir. Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain cobicistat interactions. Cobicistat and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications. DB09065
4 Darunavir Darunavir, co-administered with ritonavir, and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor. DB01264
5 Delavirdine For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted DB00705
6 Didanosine For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults. DB00900
7 Dolutegravir Dolutegravir is indicated in combination with other antiretroviral agents for the treatment of patients with HIV-1 infection that comply with the characteristics of being adults or children aged 12 years and older and present at least a weight of 40 kg.[A7520] The FDA combination therapy approval of dolutegravir and rilpivirine is indicated for adults with HIV-1 infections whose virus is currently suppressed (< 50 copies/ml) on a stable regimen for at least six months, without history of treatment failure and no known substitutions associated to resistance to any of the two components of the therapy.[L1031] DB08930
8 Efavirenz For use in combination treatment of HIV infection (AIDS) DB00625
9 Elvitegravir Elvitegravir in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) is indicated for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. DB09101
10 Emtricitabine Indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and for postexposure prophylaxis of HIV infection in health care workers and others exposed occupationally or nonoccupationally via percutaneous injury or mucous membrane or nonintact skin contact with blood, tissues, or other body fluids associated with risk for transmission of the virus. DB00879
11 Enfuvirtide Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. DB00109
12 Fosamprenavir Indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. The use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in HIV infected adults. DB01319
13 Indinavir Indinavir is an antiretroviral drug for the treatment of HIV infection. DB00224
14 Lopinavir Indicated in combination with other antiretroviral agents for the treatment of HIV-infection. DB01601
15 Maraviroc For treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. DB04835
16 Nelfinavir Used in combination with other antiviral drugs in the treatment of HIV in both adults and children. DB00220
17 Raltegravir For the treatment of HIV-1 infection in conjunction with other antiretrovirals. DB06817
18 Rilpivirine Rilpivirine, in combination with other agents, is indicated for the treatment of HIV-1 infections in antiretroviral treatment-naive patients with HIV-1 RNA ≤100,000 copies/mL and CD4+ cell count >200 cells/mm3.[L1030] The FDA combination therapy approval of rilpivirine and dolutegravir is indicated for adults with HIV-1 infections whose virus is currently suppressed (< 50 copies/ml) on a stable regimen for at least six months, without history of treatment failure and no known substitutions associated to resistance to any of the two components of the therapy.[L1031] DB08864
19 Saquinavir For the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues. DB01232
20 Tenofovir alafenamide Tenofovir alafenamide is indicated for the treatment of chronic hepatitis B in adult patients with compensated liver disease.[L6241] In combination with [emtricitabine] and other antiretrovirals, it is indicated for the treatment of HIV-1 infection in patients with a weight higher than 35 kg. When combined with antiretrovirals other than protease inhibitors that require a CYP3A inhibitor, it can be used in pediatric patients weighing between 25 and 35 kg.[L4388] In the combination product with emtricitabine and [bictegravir], tenofovir alafenamide is considered as a complete regimen for the treatment of HIV-1 infection in treatment-naive patients or in patients virologically suppressed for at least 3 months with no history of treatment failure.[L6277] Additionally, the combination product including [elvitegravir], [cobicistat], emtricitabine and tenofovir alafenamide and the combination product including emtricitabine, [rilpivirine] and tenofovir alafenamide can be used in the treatment of HIV-1 infection in patients older than 12 years with no previous antiretroviral therapy history or who are virologically suppressed for at least 6 months with no history of treatment failure.[L6280] Lastly, the combination product including [darunavir], cobicistat, emtricitabine, and tenofovir alafenamide is indicated for the treatment of HIV-1 infection in adults without prior antiretroviral therapy or in patients virologically suppressed for 6 months and no reported resistance to darunavir or tenofovir.[L6283] DB09299
21 Tenofovir disoproxil Tenofovir is indicated in combination with other antiretroviral agents for the management of HIV-1 infection in adults and pediatric patients 2 years of age and older. It is also indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older [FDA label]. This drug is also a component of multiple products used for the management of HIV-1 infection [F3418], [F3421]. Safety and effectiveness of tenofovir disoproxil in pediatric patients younger than 2 years of age has not been established to this date [FDA label]. DB00300
22 Tipranavir For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors. DB00932

Drugs for Human Immunodeficiency Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1065)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
2
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
3
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
4
Sodium Tetradecyl Sulfate Approved, Investigational Phase 4 1191-50-0, 139-88-8 5248 14492
5
Sodium sulfate Approved, Vet_approved Phase 4 7757-82-6
6
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
7
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
8
Lopinavir Approved Phase 4 192725-17-0 92727
9
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
10
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
11
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
12
leucovorin Approved Phase 4 58-05-9 143 6006
13
Acyclovir Approved Phase 4 59277-89-3 2022
14
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
15
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
16
Atovaquone Approved Phase 4 95233-18-4 74989
17
Zalcitabine Approved, Investigational Phase 4 7481-89-2 24066
18
Fosamprenavir Approved Phase 4 226700-79-4 131536
19
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
20
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
21
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
22
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
23
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
24
Megestrol acetate Approved, Investigational, Vet_approved Phase 4 595-33-5 11683
25
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
26
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
27
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
28
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
29
Acetaminophen Approved Phase 4 103-90-2 1983
30
Losartan Approved Phase 4 114798-26-4 3961
31
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
32
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
33
Copper Approved, Investigational Phase 4 7440-50-8 27099
34
Desogestrel Approved Phase 4 54024-22-5 40973
35
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
36
Ferrous fumarate Approved Phase 4 141-01-5
37
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
38
carbamide peroxide Approved Phase 4 124-43-6
39
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
40
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
41
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
42
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
43
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
44
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
45
Desipramine Approved, Investigational Phase 4 50-47-5 2995
46
Oxandrolone Approved, Investigational Phase 4 53-39-4 5878
47
Proguanil Approved Phase 4 500-92-5 4923
48
Temazepam Approved, Investigational Phase 4 846-50-4 5391
49
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468
50
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472

Interventional clinical trials:

(show top 50) (show all 6139)
# Name Status NCT ID Phase Drugs
1 Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a "Real Life" Study Unknown status NCT01049685 Phase 4 First-line Antiretroviral Therapy
2 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
3 Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
4 An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir(RAL)in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
5 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
6 Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
7 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
8 Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients Unknown status NCT02370979 Phase 4
9 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
10 Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 Unknown status NCT01235013 Phase 4 Maraviroc
11 The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial Unknown status NCT02401828 Phase 4 Dolutegravir
12 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adults Unknown status NCT01017172 Phase 4
13 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
14 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
15 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
16 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
17 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
18 Pilot Study of the Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection Unknown status NCT01343225 Phase 4 atripla;darunavir ritonavir raltegravir
19 Systematic Empirical vs. Test-guided Anti-tuberculosis Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating Antiretroviral Therapy With CD4 Cell Counts <100/mm3: the STATIS Randomized Controlled Trial Unknown status NCT02057796 Phase 4 ART (Atripla, Truvada, Efavirenz, Combivir);Rifampin, isoniazid, pyrazinamide, ethambutol
20 A Phase IV Open-label, Multi-centre, Randomised, Dual-arm, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Dolutegravir Unknown status NCT02285374 Phase 4 Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir
21 The Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection Unknown status NCT03205566 Phase 4 Raltegravir 400Mg Tab;Lamivudine 150Mg Tablet
22 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4 Reducing dose of Lopinavir;Reducing dose of efavirenz
23 A Randomized Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
24 An Open, Single-Arm, Multi-Center, Phase IV Pilot Study of Treatment of Antiretroviral Naive HIV-1 Infected Patients With Tenofovir Disoproxil Fumarate in Combination With Emtricitabine and Zidovudine Unknown status NCT00199121 Phase 4 Zidovudine (drug)
25 A Pilot Study of Highly Active Antiretroviral Therapy Using Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Antiretroviral Naive HIV-Infected Subjects Unknown status NCT00740064 Phase 4 Raltegravir and Abacavir/Lamivudine
26 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
27 A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
28 A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who Are Antiretroviral Therapy Naive Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
29 A Phase 4, Single Arm, Open Label, Pilot Study of Maraviroc (Celsentri) in Combination With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients. Unknown status NCT01013987 Phase 4 maraviroc;Raltegravir;Darunavir/ritonavir
30 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
31 Comparison Between Classical 4-point Canne and 4-roll Canne on Gait Parameters (Gait Speed and Energy Cost) as Walking Aids After Stroke. A Multicentric Randomized Controled Cross-over Study Unknown status NCT02279069 Phase 4
32 Pilot, Open-label, Randomized, Single-center Study to Asses a Simplification Strategy From Protease Inhibitors to Raltegravir: Once Daily Isentress (ODIS) Unknown status NCT00941083 Phase 4 Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy)
33 A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
34 Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860 Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
35 A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy Unknown status NCT02322099 Phase 4 Alendronate;Placebo;Tenofovir disoproxil
36 A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT) Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
37 Hepatic Safety of Raltegravir-based and Efavirenz-based Antiretroviral Regimens in Antiretroviral-Naïve HIV-infected Subjects Co-Infected With Hepatitis C Unknown status NCT01147107 Phase 4 Raltegravir;Efavirenz
38 The Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha) in Patients With Conductive or Mixed Hearing Loss, or Unilateral Deafness Unknown status NCT01264510 Phase 4
39 Maraviroc Abacavir STudy - Effect on Endothelial Recovery Unknown status NCT01389063 Phase 4 Maraviroc
40 A Pilot Randomized, Open Label Study to Evaluate Efficacy and Safety of the Combination of RAL+ATV/r in Comparison With TDF/FTC+ATV/r in HIV Infected Patients, Who Failed an Initial NNRTI Containing Regimen Unknown status NCT01829802 Phase 4 Ritonavir boosted Atazanavir;Raltegravir;TDF/FTC (or 3TC)
41 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
42 Curing HCV in Incarcerated Patients Unknown status NCT03018353 Phase 4 Patients receiving Sof/Vel (Epclusa) and Navigation services
43 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults Unknown status NCT01782950 Phase 4 Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
44 Treating HIV-infected Elite Controllers as a Model of HIV Remission Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
45 Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations Unknown status NCT01347294 Phase 4 Bleomycin;Fibrovein;Bleomycin + Fibrovein
46 Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care Unknown status NCT01195493 Phase 4
47 Sequenced Therapies for Comorbid and Primary Insomnias Unknown status NCT01651442 Phase 4 Zolpidem;Trazodone
48 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
49 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
50 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules

Search NIH Clinical Center for Human Immunodeficiency Virus Type 1

Inferred drug relations via UMLS 72 / NDF-RT 51 :


abacavir
Abacavir
abacavir sulfate
Amprenavir
Atazanavir
Cobicistat
Darunavir
Delavirdine
Delavirdine
Delavirdine Mesylate
Didanosine
Didanosine
Dolutegravir
efavirenz
Efavirenz
Elvitegravir
Emtricitabine
enfuvirtide
Enfuvirtide
Fosamprenavir
Immunoglobulins, Intravenous
Indinavir
Indinavir
Indinavir Sulfate
Lamivudine
lopinavir
Lopinavir
Maraviroc
Nelfinavir
Nelfinavir
Nelfinavir Mesylate
Nevirapine
Raltegravir
Rilpivirine
Ritonavir
Saquinavir
Saquinavir
saquinavir mesylate
Stavudine
Tenofovir
Tenofovir alafenamide
tenofovir alafenamide fumarate
Tenofovir disoproxil
Tenofovir disoproxil fumarate
Tipranavir
Zalcitabine
Zidovudine

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Human Immunodeficiency Virus Type 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Human Immunodeficiency Virus Type 1:
AGS-004, electroporated mature dendritic cells for HIV
Embryonic/Adult Cultured Cells Related to Human Immunodeficiency Virus Type 1:
Maturated and electroporated dendritic cells PMIDs: 20636001

Genetic Tests for Human Immunodeficiency Virus Type 1

Genetic tests related to Human Immunodeficiency Virus Type 1:

# Genetic test Affiliating Genes
1 Human Immunodeficiency Virus Type 1, Susceptibility to 29 CCL11 CCL2 CCL3 CCL3L1 CD209 CX3CR1 CXCL12 CXCR1 HLA-C IFNG IL10 IL4R KIR3DL1 TLR3

Anatomical Context for Human Immunodeficiency Virus Type 1

MalaCards organs/tissues related to Human Immunodeficiency Virus Type 1:

41
Testes, T Cells, Bone, Brain, Breast, Monocytes, Endothelial

Publications for Human Immunodeficiency Virus Type 1

Articles related to Human Immunodeficiency Virus Type 1:

(show top 50) (show all 50022)
# Title Authors PMID Year
1
Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC) 9 38 8 71
9430590 1998
2
Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. 9 38 8 71
9252328 1997
3
Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. 38 8 71
15564514 2004
4
A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. 8 71
22174453 2012
5
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. 8 71
19935663 2009
6
MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission. 8 71
14571188 2003
7
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. 8 71
11121048 2000
8
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. 8 71
8751444 1996
9
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. 8 71
8756719 1996
10
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. 9 38 8
17243065 2007
11
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. 9 38 8
12134147 2002
12
Genetic acceleration of AIDS progression by a promoter variant of CCR5. 9 38 8
9836644 1998
13
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. 9 38 8
8791590 1996
14
Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. 38 8
22190037 2011
15
The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. 38 8
20871604 2010
16
Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. 38 8
17906637 2007
17
Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. 38 8
17306567 2007
18
A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients. 9 8
17360650 2007
19
Structural definition of a conserved neutralization epitope on HIV-1 gp120. 38 8
17301785 2007
20
The case for selection at CCR5-Delta32. 9 71
16248677 2005
21
Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. 9 8
16189667 2005
22
Influence of host genetic variation on susceptibility to HIV type 1 infection. 38 8
15630678 2005
23
Human genes that limit AIDS. 38 8
15167933 2004
24
Modulating influence on HIV/AIDS by interacting RANTES gene variants. 38 8
12114533 2002
25
A homologous naturally occurring mutation in Duffy and CCR5 leading to reduced receptor expression. 9 71
11369664 2001
26
Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. 38 8
11386265 2001
27
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. 38 8
10073943 1999
28
CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). 9 71
9742978 1998
29
Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users. 9 71
9600249 1998
30
Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. 9 71
9132277 1997
31
Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. 8
29302013 2018
32
HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. 8
26416734 2015
33
SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. 8
26416733 2015
34
HIV Blocks Interferon Induction in Human Dendritic Cells and Macrophages by Dysregulation of TBK1. 8
25855743 2015
35
TOE1 is an inhibitor of HIV-1 replication with cell-penetrating capability. 8
26056259 2015
36
PQBP1 Is a Proximal Sensor of the cGAS-Dependent Innate Response to HIV-1. 8
26046437 2015
37
Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. 8
22988032 2012
38
T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. 8
22190036 2011
39
Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. 71
21911422 2011
40
Genetic diversity at endoplasmic reticulum aminopeptidases is maintained by balancing selection and is associated with natural resistance to HIV-1 infection. 8
20843824 2010
41
Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. 8
20445539 2010
42
Concerted action of cellular JNK and Pin1 restricts HIV-1 genome integration to activated CD4+ T lymphocytes. 8
20173753 2010
43
The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry. 8
19620399 2009
44
Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B. 71
19017985 2008
45
Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. 8
18806803 2008
46
Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. 8
18621010 2008
47
Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. 8
18562290 2008
48
Identification of host proteins required for HIV infection through a functional genomic screen. 8
18187620 2008
49
A whole-genome association study of major determinants for host control of HIV-1. 8
17641165 2007
50
Filamin-A regulates actin-dependent clustering of HIV receptors. 8
17572668 2007